

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS, INC.,
Petitioner

v.

NOVO NORDISK A/S,
Patent Owner

Case IPR2023-00724
Patent 10,335,462

**EXPERT DECLARATION OF ROBIN S. GOLAND, M.D.
IN SUPPORT OF PATENT OWNER'S RESPONSE TO
PETITION FOR *INTER PARTES* REVIEW OF
U.S. PATENT NO. 10,335,462**

TABLE OF CONTENTS

I.	INTRODUCTION	2
II.	BACKGROUND AND QUALIFICATIONS.....	3
III.	PRIORITY DATE AND ONE OF ORDINARY SKILL.....	5
IV.	LEGAL STANDARDS.....	7
V.	MATERIALS RELIED UPON	10
VI.	BACKGROUND ON TYPE 2 DIABETES.....	10
VII.	THE '462 PATENT AND NOVO'S OZEMPIC® (SEMAGLUTIDE)..	13
VIII.	OBJECTIVE INDICIA OF NON-OBVIOUSNESS	21
	A. Unexpected Results With Ozempic® (semaglutide)	21
	B. Ozempic® Fulfilled a Long-Felt Need	30
	C. Ozempic® Has Received Significant Praise.....	31
	D. Ozempic® Was Met With Skepticism	33
IX.	CONCLUSION	34

I, Robin S. Goland, hereby declare under penalty of perjury:

I. INTRODUCTION

1. I have been retained by Groombridge, Wu, Baughman & Stone LLP, on behalf of Novo Nordisk A/S (“Novo Nordisk”) to provide assistance regarding U.S. Patent No. 10,335,462 (“the ’462 patent”). Specifically, I have been asked to provide my opinions regarding certain objective indicia of non-obviousness for claims 1-10 of the ’462 patent (the “Challenged Claims”). Except as otherwise indicated, I have personal knowledge of the facts set forth in this Declaration. All statements herein made of my own knowledge are true and all statements made on information and belief are believed to be true. If called upon to do so, I would testify competently thereto.

2. I am being compensated for my time at a rate of \$850 per hour. I will be reimbursed for any expenses that I incur during the course of this work. My compensation is not contingent upon the results of my study, the substance of my opinions, or the outcome of any proceeding involving the Challenged Claims. I have no financial interest in the outcome of this matter or in the pending litigations involving Novo Nordisk A/S and Novo Nordisk Inc.